Long term effect of interferon-beta on disease severity in relapsing-remitting multiple sclerosis patients;Efecto del tratamiento a largo plazo con interferón beta en la gravedad de la esclerosis múltiple remitente-recurrente

Revista de Neurologia

Volumn 50, Issue 9, 2010, Pages 529-532

  Patrucco, Liliana ^a   Rojas, Juan Ignacio ^a   Cristiano, Edgardo ^a  

^a HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

Author keywords

Beta interferon; Disease progression; Multiple sclerosis

Indexed keywords

BETA1A INTERFERON; INTERFERON BETA SERINE;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HUMAN; IMMUNOMODULATION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; RELAPSING REMITTING MULTIPLE SCLEROSIS; TREATMENT OUTCOME;

EID: 77952034634     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.5009.2009514     Document Type: Article

References (9)

1. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655-661
2. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352: 1498-1504
3. Hernández-Pérez MA, en representación del grupo de investigadores del estudio PARALEN. Seguridad y tolerabilidad en la fase inicial del tratamiento con interferón beta-1a 44 microgramos en pauta lenta frente a pauta rápida en pacientes con esclerosis múltiple (estudio PARALEN). Rev Neurol 2009; 48: 505-508
4. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996; 39: 285-294 (Pubitemid 26100751)
5. Kappos L, Traboulsee A, Constantinescu C, Eralinna JP, Forrestal F, Jongen P, et al. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology 2006; 67: 944-953 (Pubitemid 44454583)
6. Lublin FD, Reingold SC. Placebo-controlled clinical trials in multiple sclerosis: ethical considerations. National Multiple Sclerosis Society (USA) Task Force on Placebo-Controlled Clinical Trials in MS. Ann Neurol 2001; 49: 677-681 (Pubitemid 32429797)
7. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-231 (Pubitemid 13158528)
8. Rudick RA, Cutter GR, Baier M, Weinstock-Guttman B, Mass MK, Fisher E, et al. Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients. Mult Scler 2005; 11: 626-634 (Pubitemid 41685131)
9. Trojano M, Pellegrini F, Fuiani A, Paolicelli D, Zipoli V, Zimatore GB, et al. New natural history of interferon-beta-treated relapsing multiple sclerosis. Ann Neurol 2007; 61: 300-306 (Pubitemid 46676729)